Open Access Articles- Top Results for Daiichi Sankyo

Daiichi Sankyo

Daiichi Sankyo Company, Limited
Public KK
Traded as TYO: 4568
OSE: 4568
NAG: 4568
TOPIX 100 Component
Nikkei 225 Component
Industry Pharmaceutical
  • Daiichi Pharmaceutical Company
  • Sankyo Company
Founded Tokyo, Japan (2005) (by merger)
Headquarters Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan
Key people
Takashi Shoda, Chairman
Joji Nakayama, (CEO and President)

11px $ 12.006 billion USD (FY 2012)

(¥ 997.852 billion JPY) (FY 2012)
#redirect Template:If affirmed

11px $ 0.801 billion USD (FY 2012)

(¥ 66.621 billion JPY) (FY 2012)
Number of employees
32,229 (as of December 2013)
Website Official website
Footnotes / references

Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Parsippany, New Jersey.

Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.

Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

In 2009, the highly respected magazine R&D Direction honoured Daiichi Sankyo with its "Best Cardiovascular Pipeline Award".


Daiichi Sankyo was established in 2005 through the merger of Sankyo Company, Limited (三共株式会社 Sankyō Kabushiki Kaisha?) and Daiichi Pharmaceutical Company, Limited (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha?), which were century-old pharmaceutical companies based in Japan.


In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

On June 10, 2008, Daiichi Sankyo agreed to take a majority (64%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.[3][4]

In June 2008, Daiichi Sankyo acquired U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.[5]

On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkeley, California-based pharmaceutical start-up company for $805 million and an additional $130 million in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (Roche licensed) drug. [6]

On April 7, 2014, Daiichi Sankyo announced that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100% of Ranbaxy through the merger process which entails a share swap. The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.

On September 29, 2014, Daiichi agreed to acquire Ambit Biosciences for approximately $410 million, the deal will enable Daiichi to gain the Phase III cancer compound quizartinib.[7]

On April 20, 2015, the company announced it had sold off its 8.9% stake in Sun Pharmaceutical Industries it acquired when acquiring Ranbaxy, raising $3.2 billion.[8]

Products of Daiichi Sankyo Group


Daiichi Pharmaceutical

Pipeline candidates

Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:

  • ARQ 197 (Tivantinib) — Oncology
  • DS-5565 (Mirogabalin) — Chronic pain
  • PLX4032 (Vemurafenib) — Oncology
  • SUN13837 — Spinal cord injury


External links

Lua error in package.lua at line 80: module 'Module:Portal/images/j' not found.